Extra caution is appropriate in patients with active cancer, recent cancer, unexplained masses, unexplained weight loss, pregnancy, breastfeeding, known allergy to peptide products, active infection, immune compromise, significant liver or kidney disease, active inflammatory or autoimmune disease flares, unusual clotting history, uncontrolled cardiovascular disease, use of chemotherapy or immune-modifying biologic therapy, and competitive athletes subject to anti-doping rules
Tirzepatide starts at 2.5 mg weekly (Mounjaro), increasing by 2.5 mg every 4 weeks until the desired maintenance dose (up to 15 mg ) is reached
Q: Does GHK-Cu affect hormones
Here is a side-by-side comparison: Neither approach is universally better
Within hours of receiving your injection, the medication begins influencing two key hormone systems: GLP-1 and GIP receptors
Morning stiffness limits activities for the first hour after waking